August 2024 Br J Cardiol 2024;31(suppl 1):S16–S20 doi:10.5837/bjc.2024.s04
Pyotr Telyuk, David Austin, Paul Williams, Ahai Luvai, Azfar Zaman
Introduction Lipoprotein(a) (figure 1) has emerged as an independent and causal risk factor for cardiovascular diseases (CVDs) and cerebrovascular diseases with prospective epidemiological studies demonstrating a link between elevated Lp(a) levels and increased incidence of ischaemic heart disease (IHD) and myocardial infarction (MI).1 The value of this association is that it was seen to be independent of traditional cardiovascular (CV) risk factors including diabetes, hypertension and smoking.1 Moreover, Lp(a) levels greater than 50 mg/dL were associated with a threefold increase in acute coronary syndrome (ACS) in younger patient cohorts (
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits